英夫利昔单抗治疗强直性脊柱炎髋关节病变的疗效观察

A clinical study of Infliximab in the treatment of ankylosing spondylitis hip joint lesion

目的观察英夫利昔单抗治疗强直性脊柱炎(AS)髋关节病变的疗效。方法 15例AS患者同时伴有髋关节病变,第0、2、6周给予静脉滴注英夫利昔单抗(3 mg/kg)治疗。评价治疗前和治疗后第6、12周时AS病情活动指数评分(BASDAI)、AS功能指数评分(BASFI)、Harris髋关节评分、腰痛、腰背晨僵时间以及红细胞沉降率(ESR)、C反应蛋白(CRP)的变化。结果 15例患者Harris髋关节评分治疗后第6、12周显著高于治疗前(P<0.01);BASDAI、BAS-FI、腰痛、腰背晨僵时间以及ESR、CRP治疗后第6、12周与治疗前相比明显下降(P<0.01)。治疗期间1例患者在第6周出现输液反应。结论英夫利昔单抗治疗AS髋关节病变起效快、疗效好,而且不良反应轻,同时安全性高。

Objective To observe the therapeutic effect of Infliximab on intractable ankylosing spondylitis （AS） related hip joint lesion. Methods Fifteen patients with AS with hip joint lesion were included into this study. Infliximab 3 mg/kg was infused at weeks 0, 2, 6. The parameters including bath ankyiosing spondylitis disease activity index （BASDAI）, bath anky- losing spondylitis functional index （BASF1）, harris hip score, backache, morning stiffness, erythrucyte sedimentation rate （ESR） and C-reactive protein （CRP） were evaluated before and after the treatment at week 6 and 12. Results Harris score of the hips increased significantly at weeks 6 and 12 after treatment （P 〈 0.01）; BASDAI, BASF!, backache, morning stiffness, ESR and CRP were decreased after treatment at weeks 6 and 12 （P 〈 0.01）; A patient observed transfusion reaction at week 6. Conclusion Infliximab treatment of AS with hip joint lesion is effective for treatment of hip joint function and without adverse reactions, while safe for the treatment of AS, can be the preferred drug of hip disease.